| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
The targets of A 802715 are not explicitly defined in the available literature, but based on its mechanism of action, it appears to modulate inflammatory pathways by reducing pro-inflammatory mediators and elevating anti-inflammatory factors such as IL-10R and TNFR. It also modulates dopamine release, suggesting interaction with dopaminergic signaling pathways. As a methylxanthine derivative, it may also interact with adenosine receptors or phosphodiesterases, which are common targets of this class of compounds. However, the precise molecular targets of A 802715 require further investigation.
|
|---|---|
| ln Vitro |
By using the vital dye staining assay, the methylxanthine derivative A802715's toxicity was assessed against two human melanoma lines, Be11 and MeWo, as well as two human squamous cell carcinoma cell lines, 4197 and 4451. A802715 is the most hazardous, with a TD50 of 0.9-1.1 mM. BrdU incorporation demonstrated that A802715 significantly increased radiation-induced suppression of S phase entry in p53 wt cells. A802715 either prolongs G2/M arrest or is ineffective based on the cell line's p53 status [1].
In vitro, A 802715 demonstrates immunomodulatory activity. It modulates inflammatory pathways by reducing pro-inflammatory mediators and increasing anti-inflammatory factors. It has also been reported to modulate dopamine release in neuronal preparations. However, detailed in vitro activity data, including IC50 or EC50 values, are not extensively reported in the available literature. The compound's pharmacological precision makes it a valuable tool for dissecting receptor-level functions in vitro. |
| ln Vivo |
In vivo data for A 802715 are not extensively reported in the available literature. Based on its immunomodulatory and dopamine-modulating activities, the compound has potential for in vivo applications in studying neuroinflammation, reward pathways, and nicotine-related behaviors. However, specific in vivo efficacy data, including animal models, dosing regimens, and pharmacokinetic-pharmacodynamic relationships, are not detailed in the available sources.
|
| Enzyme Assay |
Specific in vitro enzyme/receptor binding assay protocols for A 802715 are not detailed in the available literature. As a compound that modulates inflammatory pathways and dopamine release, its activity could be assessed in receptor binding assays for adenosine receptors or other potential targets. However, the precise molecular targets of A 802715 have not been fully elucidated, and therefore specific assay protocols are not available.
|
| Cell Assay |
Cellular assays for A 802715 are performed in various cell types to assess its immunomodulatory and neuropharmacological effects. In immune cells, the compound's effects on the production of pro-inflammatory and anti-inflammatory cytokines are measured. In neuronal cells, its effects on dopamine release are assessed. These assays are used to study the compound's mechanism of action and its potential therapeutic applications.
|
| Animal Protocol |
In vivo animal studies with A 802715 are not extensively documented in the available literature. Based on its modulation of inflammatory pathways and dopamine release, potential in vivo models could include models of neuroinflammation, addiction, or neurodegenerative diseases. In such studies, A 802715 would be administered systemically, and endpoints would include behavioral measures, neurochemical changes, and inflammatory markers. However, specific protocols are not detailed in the available sources.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for A 802715 are not extensively reported. The compound is a methylxanthine derivative, a class of compounds that can have variable pharmacokinetic properties. It has a TD50 (toxic dose of 50%) of 0.9-1.1 mM. However, detailed pharmacokinetic parameters such as absorption, distribution, metabolism, excretion, half-life, and bioavailability are not available in the literature for this research compound.
|
| Toxicity/Toxicokinetics |
The toxicity of A 802715 is indicated by its TD50 of 0.9-1.1 mM. However, comprehensive toxicology data for this compound are not extensively reported. The compound is classified as a research-use-only chemical and is not intended for human consumption. Specific toxicological data, including acute toxicity, genotoxicity, and target organ effects, are not reported in the available literature.
|
| References | |
| Additional Infomation |
A 802715 is a research-grade compound not approved for clinical use. Its primary applications are in neuroinflammation, immunology, and neuroscience research. The compound is used to study the role of inflammatory pathways in neurological and psychiatric disorders, as well as the mechanisms of reward and addiction. Its ability to modulate both inflammatory and dopaminergic pathways makes it a unique tool for studying the interplay between these systems.
|
| Molecular Formula |
C16H26N4O3
|
|---|---|
| Molecular Weight |
322.41
|
| Exact Mass |
322.2
|
| CAS # |
107767-58-8
|
| PubChem CID |
129959
|
| Appearance |
White to off-white solid powder
|
| Density |
1.22g/cm3
|
| Boiling Point |
526.7ºC at 760 mmHg
|
| Flash Point |
272.3ºC
|
| Vapour Pressure |
6.4E-12mmHg at 25°C
|
| Index of Refraction |
1.584
|
| LogP |
1.247
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
23
|
| Complexity |
455
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(N1CCCCC(C)(O)C)N(C)C2=C(N(CCC)C=N2)C1=O
|
| InChi Key |
SBKAARSDXHSHSM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H26N4O3/c1-5-9-19-11-17-13-12(19)14(21)20(15(22)18(13)4)10-7-6-8-16(2,3)23/h11,23H,5-10H2,1-4H3
|
| Chemical Name |
1H-Purine-2,6-dione, 3,7-dihydro-1-(5-hydroxy-5-methylhexyl)-3-methyl-7-propyl-
|
| Synonyms |
A-802715 A802715A 802715
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~190 mg/mL (~589.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 7.5 mg/mL (23.26 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 7.5 mg/mL (23.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 75.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 7.5 mg/mL (23.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1016 mL | 15.5082 mL | 31.0164 mL | |
| 5 mM | 0.6203 mL | 3.1016 mL | 6.2033 mL | |
| 10 mM | 0.3102 mL | 1.5508 mL | 3.1016 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
